Cytek Biosciences, Inc. (CTKB)

Over the past six months, Cytek Biosciences' stock price has experienced a decline. Between October 11, 2024, and October 10, 2025, the share price decreased by 23.05%. From the beginning of 2025 to October 2025, CTKB shares decreased by 36.1%. Around September 25, 2025, the company's market cap fell after a 13% drop in share price, contributing to a one-year loss of 33% for shareholders. Cytek Biosciences is scheduled to report its third-quarter 2025 financial results on November 5, 2025.

While Cytek Biosciences acknowledges "seasonal demands" as a factor that could negatively affect its ability to accurately forecast customer demand and manage inventory, the provided information does not detail a strong, predictable seasonal pattern for its specific products or services. The broader flow cytometry market, in which Cytek operates, is driven by ongoing research and development investments in biotechnology, life science, and biopharmaceutical research, as well as increasing adoption in clinical diagnostics and the rising prevalence of chronic and infectious diseases. These drivers suggest a more continuous demand rather than pronounced seasonality.

Cytek Biosciences, Inc. specializes in cell analysis solutions, providing tools that facilitate scientific advancements in biomedical research and clinical applications. The company's core business revolves around its patented Full Spectrum Profiling (FSP) technology, which enables high-resolution, high-content, and high-sensitivity cell analysis. Major products include Cytek Aurora and Northern Lights systems, Cytek Aurora CS cell sorter, Cytek Orion reagent cocktail preparation system, Enhanced Small Particle (ESP) detection technology, Amnis and Guava brands, and reagents, software, and services. Cytek's products are used in diverse applications such as immunophenotyping, cell signaling studies, oncology research, infectious diseases, immunology, immunotherapy, immuno-oncology, and drug discovery. While most of Cytek's products are for research use only, the Northern Lights CLC system is available for clinical use in China and the European Union.

Cytek Biosciences is headquartered in Fremont, California, and has a global distribution network, serving academic institutions, biopharmaceutical companies, and clinical laboratories across North America, Europe, and Asia. It distributes its products through direct sales forces and support organizations in North America, Europe, China, and the Asia-Pacific regions, and through distributors or sales agents in Europe, Latin America, and the Middle East countries. In October 2025, Cytek Biosciences expanded its European presence by relocating its European headquarters to a new facility in Amsterdam's Life Sciences District, increasing its European footprint by over 40%. The majority of the company's revenue is generated from the United States.

In the past year, Cytek Biosciences has actively engaged in various initiatives that generally contribute positively to its brand reputation. These include the expansion of its European presence in Amsterdam, the launch of the Aurora Evo System and Cytek Muse Micro System, participation in global conferences such as ICCS, ESCCA, CYTO, and IMMUNOLOGY2025, achieving ISO 13485 certification at its headquarters, and launching the Cytek Reveal Roadshow. These events demonstrate Cytek's focus on innovation, market expansion, customer engagement, and quality, which are generally positive for brand reputation.

Cytek Biosciences (NASDAQ: CTKB) is owned by 62.44% institutional shareholders, 22.36% Cytek Biosciences insiders, and 15.20% retail investors. Institutional investors collectively hold 100,682,199 shares. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Brown Capital Management LLC, Hillhouse Capital Advisors, Ltd., Topline Capital Management LLC, State Street Corp, and Dimensional Fund Advisors LP. Major individual owners (insiders) include Ra Capital Management LP, Wenbin Jiang (CEO), and Ming Yan.